Back
ESC Professional Premium Access

Dronedarone versus sotalol in patients with atrial fibrillation: a systematic literature review and network meta-analysis

Session: Atrial fibrillation: rate or rhythm control
Topic: Rhythm Control, Antiarrhythmic Drugs
Speaker: Professor J. Camm (London, GB)
Event: ESC Congress 2022

Congress Presentation

Add to my library

Like

About the speaker

Professor John Camm

St George's University of London, London (United Kingdom of Great Britain & Northern Ireland)
78 presentations
7 followers

5 more presentations in this session

Association between early rhythm control and the risk of dementia in patients with atrial fibrillation and prior history of stroke: a nationwide population-based study

Speaker: Doctor S. Lee (Seoul, KR)

Access
Abstract
Slides
Like
Thumbnail

Effect of dronedarone versus placebo on atrial fibrillation progression: a post-hoc analysis from ATHENA trial

Speaker: Professor C. Blomstrom-Lundqvist (Orebro, SE)

Access
Abstract
Slides
Like
Thumbnail

Holistic approach of ablation versus antiarrhythmic drugs for efficacy, safety, and quality of life improvement in rhythm control of atrial fibrillation: a meta-analysis of randomized trials

Speaker: Mr G. Prana Jagannatha (Denpasar, ID)

Access
Abstract
Slides
Like
Thumbnail

Sex differences in the use of rhythm control strategies in patients with atrial fibrillation in FinACAF study

Speaker: Ms K. Kalatsova (Helsinki, FI)

Access
Abstract
Slides
Like
Thumbnail

Prevalence of modifiable risk factors and related poor cardiovascular outcomes following atrial fibrillation ablation

Speaker: Doctor K. Stout (Omaha, US)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Atrial fibrillation: rate or rhythm control

Speakers: Professor J. Camm, Doctor S. Lee, Professor C. Blomstrom-Lundqvist, Mr G. Prana Jagannatha, Ms K. Kalatsova...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources